Comparison of the differences and advantages between domestic and imported versions of Afatinib

Afatinib is a second-generation EGFR-TKI targeted drug, mainly used to treat patients with advanced non-small cell lung cancer with EGFR gene mutations. The drug can irreversibly inhibit the EGFR signaling pathway and has strong activity against a variety of sensitive mutations. Afatinib has been officially launched in China and has been included in medical insurance. Patients can purchase it with a prescription in hospital pharmacies, reducing their financial burden.

The domestic version of afatinib has been launched one after another after the patent expires. Its active ingredients are the same as the original drug and have passed the consistency evaluation of the national drug regulatory department. The price of the domestic version is relatively low, and after being included in medical insurance, the reimbursement ratio is higher, and the patient's out-of-pocket expenses are significantly reduced. In addition, the supply chain of domestically produced drugs is stable and can be obtained directly in major hospitals and pharmacies, making it suitable for patients who require long-term standardized treatment.

Abroad, afatinib includes original drugs and generic drugs. The price of the original version in India is about more than 5,000 yuan; while the generic version includes versions in India, Laos, Bangladesh, etc., with prices ranging from a few hundred yuan to more than 2,000 yuan. The ingredients of these generic drugs are basically the same as those of the original drugs, and their efficacy is similar. However, regulatory standards vary from country to country, so you need to pay attention to the formality of the channels when purchasing.

Generally speaking, the domestic version has advantages in price and medical insurance policies, and is suitable for patients who want to reduce medication costs; the original drug is more secure in terms of brand name and international clinical use experience; the imported generic drug is more cost-effective, but the source must be reliable. Patients should consider their condition, financial status and doctor's advice when making selections to ensure long-term, standardized and effective targeted therapy.

Reference materials:https://www.drugs.com/